Analyses of efficacy and safety of off-label use of amlodipine besylate in resistant hypertension patients
Objective To evaluate the efficacy and safety of amlodipine besylate at doses exceeding the drug instructions in clinical practice,and to promote rational drug use in clinical practice.Method From January 1,2021 to December 31,2021,a total of 2 438 patients who exceeded the prescribed dosage of amlodipine besylate were selected from the First Affiliated Hospital of Zhengzhou University.Patients with refractory hypertension(RH)with a daily dose greater than 10 mg were screened,and their basic information and overdose usage were collected.The blood pressure values of the patients before and on the 7th day after the overdose were recorded,as well as the changes in heart rate and renal function parameters before and after the overdose of amlodipine besylate.Further evaluate and analyze the effectiveness and safety of high-dose medication.Results The results showed that in 2021,a total of 193 patients with refractory hypertension were treated with high-dose amlodipine besylate in the hospital,of which 118 were from the nephrology department,and 72％were patients with chronic kidney disease(CKD)stage five.After high-dose medication,the patient's blood pressure significantly decreased,and the maximum blood pressure drop and blood pressure compliance rate were observed at a daily dose of 20-30 mg.There was no significant difference in the effective rate and blood pressure compliance rate of patients in different age groups after high-dose medication,but the incidence of adverse reactions increased in patients over 40 years old,with an overall adverse reaction rate of 24％.Conclusion The majority of patients receiving high-dose amlodipine besylate in this hospital are CKD patients,and the majority of patients show significant improvement in blood pressure control after high-dose use.Among them,amlodipine besylate with a daily dose of 20-30 mg has the best antihypertensive effect and good safety.
amlodipine besylateresistant hypertensionoff-label drug useefficacysafety
NETL
NSTL
万方数据
维普
